Mark Boguniewicz, [professor of pediatrics] from University of Colorado School of Medicine in Aurora, and colleagues evaluated the impact of type 2 comorbidities on the response to and safety of dupilumab in young children with AD. The analysis included children (aged 6 months to 5 years) with moderate-to-severe AD.
CU Anschutz
Administrative Pavilion
13123 E. 16th Ave.
B065
Aurora, CO 80045